Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00447564 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
A Phase 3 study, sponsored by Titan Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 163
- Enrollment target
NCT00447564 is a Phase 3 study that has completed, run by Titan Pharmaceuticals. The registered enrollment target is 163 participants.
The verdict
NCT00447564, a Phase 3 study, has completed, sponsored by Titan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 163 participants
- Enrollment target
Study Summary
Buprenorphine (BPN) is an approved treatment for opioid dependence, however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patients with opioid dependence.
Interventions
- DRUG placebo
- DRUG Probuphine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00447564
The ClinicalTrials.gov registry entry for NCT00447564 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Titan Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00447564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00447564 about?
NCT00447564 is a clinical study titled "Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence". Buprenorphine (BPN) is an approved treatment for opioid dependence, however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 mon...
What is the current status of trial NCT00447564?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 163 participants. The study started on 2006-10. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00447564?
The interventions under investigation include: placebo (DRUG), Probuphine (DRUG).
Who is sponsoring clinical trial NCT00447564?
This trial is sponsored by Titan Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.